These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 19875919)

  • 1. The relationship between nonalcoholic fatty liver disease and the severity of coronary artery disease in patients with metabolic syndrome.
    Uzun M; Yiğiner O; Kirilmaz A
    Turk Kardiyol Dern Ars; 2009 Jul; 37(5):364; author reply 365. PubMed ID: 19875919
    [No Abstract]   [Full Text] [Related]  

  • 2. Torcetrapib and atorvastatin.
    Shear CL
    N Engl J Med; 2005 Oct; 353(14):1527-9; author reply 1527-9. PubMed ID: 16207861
    [No Abstract]   [Full Text] [Related]  

  • 3. Dramatic regression of three-vessel disease under statin treatment in patients with stable angina pectoris.
    Ercan S; Sari I; Davutoglu V
    Ther Adv Cardiovasc Dis; 2012 Dec; 6(6):259-60. PubMed ID: 23196941
    [No Abstract]   [Full Text] [Related]  

  • 4. Statin treatment in patients with elevated liver enzymes: pitch to proceed.
    Berkelhammer C; Lerma EV
    J Clin Lipidol; 2012; 6(4):310-1. PubMed ID: 22836066
    [No Abstract]   [Full Text] [Related]  

  • 5. Statin therapy for subclinical atherosclerosis in primary prevention: time to prove it?
    Villines TC
    JACC Cardiovasc Imaging; 2012 Mar; 5(3):261-3. PubMed ID: 22421170
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage).
    Han KH; Rha SW; Kang HJ; Bae JW; Choi BJ; Choi SY; Gwon HC; Bae JH; Hong BK; Choi DH; Han KR
    J Clin Lipidol; 2012; 6(4):340-51. PubMed ID: 22836071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting specific traditional risk factors to improve cardiovascular outcomes: Sound or flawed?
    Yeboah J
    Atherosclerosis; 2013 Feb; 226(2):335-6. PubMed ID: 23153621
    [No Abstract]   [Full Text] [Related]  

  • 8. Imaging of a regressive coronary soft plaque under lipid lowering therapy by multi-slice computed tomography.
    Burgstahler C; Reimann A; Beck T; Kuettner A; Heuschmid M; Kopp AF; Schroeder S
    Int J Cardiovasc Imaging; 2006 Feb; 22(1):119-21. PubMed ID: 16374526
    [No Abstract]   [Full Text] [Related]  

  • 9. Profound regression of coronary atherosclerosis with statins.
    Abdallah MH; Karrowni W; Dakik HA
    Can J Cardiol; 2006 Jun; 22(8):709. PubMed ID: 16802002
    [No Abstract]   [Full Text] [Related]  

  • 10. Qualitative plaque stabilization but not quantitative plaque regression.
    Nishigaki K
    Circ J; 2012; 76(4):809-11. PubMed ID: 22451448
    [No Abstract]   [Full Text] [Related]  

  • 11. [Atorvastatin in correction of metabolic syndrome: clinico-economical assessment of efficacy].
    Khokhlov AL; Zhilina AN; Buĭdina TA
    Kardiologiia; 2006; 46(11):57-62. PubMed ID: 17183751
    [No Abstract]   [Full Text] [Related]  

  • 12. Statins, regulatory T cells, and pediatric graft coronary artery disease.
    Goldstein MR; Mascitelli L; Pezzetta F
    Pediatr Transplant; 2009 Feb; 13(1):139-40. PubMed ID: 18564306
    [No Abstract]   [Full Text] [Related]  

  • 13. Statin comparisons in controlled clinical trials.
    Citkowitz E
    Am J Cardiol; 2005 Nov; 96(10):1467-8. PubMed ID: 16275204
    [No Abstract]   [Full Text] [Related]  

  • 14. Aggressive low-density lipoprotein cholesterol lowering in secondary prevention of coronary heart disease.
    Clearfield M
    Curr Atheroscler Rep; 2006 Jan; 8(1):7-8. PubMed ID: 16455005
    [No Abstract]   [Full Text] [Related]  

  • 15. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.
    Hyogo H; Yamagishi S; Maeda S; Kimura Y; Ishitobi T; Chayama K
    Dig Liver Dis; 2012 Jun; 44(6):492-6. PubMed ID: 22265683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin is a two-edged sword in liver enzyme.
    Li N; Yang YJ
    Int J Cardiol; 2014 Feb; 171(2):e18. PubMed ID: 24360161
    [No Abstract]   [Full Text] [Related]  

  • 17. Concurrent use of clopidogrel (Plavix) and atorvasatin (Lipitor) is contraindicated.
    Chetty N; Naran NH; Munster M
    S Afr Med J; 2006 Apr; 96(4):264. PubMed ID: 16670787
    [No Abstract]   [Full Text] [Related]  

  • 18. Phospholipase A2 inhibitors in atherosclerosis: the race is on.
    Corson MA
    Lancet; 2009 Feb; 373(9664):608-10. PubMed ID: 19231615
    [No Abstract]   [Full Text] [Related]  

  • 19. [Prevention in coronary heart disease. Can a CSE inhibitor arrest calcium deposits?].
    MMW Fortschr Med; 2001 Apr; 143(14):44. PubMed ID: 11340911
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of endothelial function in patients with metabolic syndrome on bezafibrate or atorvastatin therapy.
    Hanefeld C; Bulut-Streich N; Bulut D; Graf C; Mügge A; Spiecker M
    Cardiovasc Drugs Ther; 2005 Mar; 19(2):153-5. PubMed ID: 16025235
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.